NCT03867071已完成不适用
Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients
Centre Hospitalier Universitaire de Nīmes2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2005年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- number of administered red blood cells
研究概览
简要总结
The objective of our study is to demonstrate the interest of early administration of recombinant erythropoietin in trauma patients
详细描述
Could an early use of rHuEPO (recombinant Human ErythroPOietin ) be lead to an individual benefice on transfusion savings after traumatic surgery?
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients between 18 to 65 years old
- •Patient with an ASA 1 or 2 (ASA 1 corresponding to a patient in perfect health and ASA 2 to a patient with moderate involvement and well controlled organ function)
- •patient presenting at least one of the following fractures: Basin and / or femur with surgical indication, associated or not with other fractures.
- •patient with hemoglobin between 9 and 13 g / dl at the time of admission on trauma department
排除标准
- •patient with contraindication to synthetic erythropoietin
- •Patient with intravenous iron contraindication
- •pregnant patient or with a risk of pregnancy
- •patient who has not given his consent or does not understand the protocol
- •Patient with hemodynamic instability
- •patient participating in another research protocol for less than 3 months.
研究组 & 干预措施
Placebo (PLA) group
Placebo Comparator
干预措施: placebo injection (Other)
erythropoietin (EPO) group
Experimental
干预措施: recombinant erythropoietin injection (Other)
结局指标
主要结局
number of administered red blood cells
时间窗: Day 30
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Erythropoietin in Premature Infants to Prevent EncephalopathyPremature InfantNCT02550054Children's Hospital of Fudan University58
已完成
1 期
Safety Study of Erythropoietin (EPO) in Parkinson's DiseaseParkinson DiseaseNCT01010802International Center for Neurological Restoration, Cuba10
已完成
1 期
Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1Cerebral PalsyNCT01586052MinYoung Kim, M.D.11
已完成
2 期
Does Erythropoietin Improve Outcome in Very Preterm Infants?Developmental Psychomotor DisordersCerebral PalsyIntracranial HemorrhagePeriventricular LeukomalaciaNCT00413946Swiss Neonatal Network420
已完成
不适用
A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease PatientsChronic DiseaseKidney DiseasesCardiovascular DiseasesNCT00563355Hospital Authority, Hong Kong66